What does a positive 24‑hour urine metanephrines result indicate and how should it be evaluated and managed?

Positive 24-Hour Urine Metanephrines: Evaluation and Management

A positive 24-hour urine metanephrines result suggests possible pheochromocytoma or paraganglioma (PPGL), but all positive results require systematic follow-up to exclude false positives before proceeding to imaging, as false-positive rates are substantial due to medications, comorbidities, and technical errors 1.

What This Result Indicates

A positive 24-hour urine metanephrines indicates:

• Primary concern: Catecholamine-secreting tumor (pheochromocytoma if adrenal, paraganglioma if extra-adrenal)
• Critical caveat: High false-positive rate compared to plasma free metanephrines (specificity 98% for urine vs 85% for plasma, but urine has fewer false positives in low-risk populations) 2

Immediate Evaluation Steps

1. Verify the Result is Real

Check for technical errors first:

• Verify the laboratory correctly entered the 24-hour urine volume—incorrect volume entry (e.g., 9750 mL instead of 975 mL) causes false elevations 3
• Confirm adequate collection (incomplete collections cause false negatives, not false positives)

2. Identify Interfering Medications

Many commonly used drugs significantly elevate urine metanephrines 4:

Drugs that increase normetanephrine:

• β-blockers
• Calcium channel blockers
• Loop diuretics
• α-blockers
• Non-metformin antidiabetic drugs
• Neuroleptics

Drugs that increase metanephrine:

• α-blockers

Drugs that decrease metanephrine (can cause false negatives):

• Non-metformin antidiabetic drugs
• Antidepressants
• Glucocorticosteroids

3. Assess Clinical Context for False Positives

High-risk conditions for false-positive urine metanephrines:

• Obstructive sleep apnea: 25.4% false-positive rate with urine vs only 3.0% with plasma metanephrines, especially in severe OSA (38.2% false-positive rate) 5
• Obesity 5
• Family history of hypertension 5

Follow-Up Algorithm

If Positive Result Confirmed:

1. Repeat testing with attention to preanalytical factors:

   • Discontinue interfering medications if possible (coordinate with prescribing physician)
   • If patient has OSA, obesity, or family history of hypertension, switch to plasma free metanephrines instead of repeating urine test 5
   • Ensure proper collection technique and volume documentation

2. If repeat testing remains positive:

   • Proceed to CT imaging as initial modality 1
   • MRI is preferred if metastatic disease suspected or radiation exposure must be limited 1
   • Consider genetic testing in all patients with confirmed PPGL (test for SDHx mutations in paraganglioma, SDHB in metastatic disease) 1

3. If functional PPGL confirmed:

   • Mandatory preoperative α-blockade to prevent perioperative complications 1
   • High-sodium diet and increased fluid intake to prevent postoperative hypotension 1
   • Minimally invasive adrenalectomy for pheochromocytomas, open resection for most paragangliomas 1

Critical Pitfalls to Avoid

• Do not proceed directly to imaging without excluding false positives—this leads to unnecessary anxiety, radiation exposure, and potential unnecessary surgery
• Do not ignore medication lists—the 2024 study demonstrates that multiple common drug classes significantly interfere with results 4
• In high-risk patients for false positives (OSA, obesity), plasma metanephrines are the superior first-line test 5
• Age and sex matter: Normetanephrine increases with age; use age-stratified reference intervals to reduce false positives 6
• Always verify laboratory data entry—volume errors are an under-recognized cause of false elevations 3

When to Use Plasma vs Urine Testing

Plasma free metanephrines preferred for:

• High-risk patients with familial endocrine syndromes (higher sensitivity: 97% vs 90%) 2
• Patients with OSA, obesity, or family history of hypertension 5
• Patients on multiple interfering medications 4

Urine metanephrines acceptable for:

• Low-risk screening populations (higher specificity: 98% vs 85%) 2
• When plasma testing unavailable

Lifelong surveillance is required after treatment to detect recurrent or metastatic disease 1.